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The “seed-and-soil hypothesis” of the mechanism of
bone metastasis (via marrow) was first described by
Stephan Paget in 1889 and is supported by findings
from animal models of bone metastasis [1]. Bone metas-
tases are a frequent complication of cancer, occurring
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Traditionally, Tc99m methyl diphosphate (MDP) bone scintigraphy provides high-sensitivity detec-
tion of skeletal metastasis from breast and lung cancers in regular follow-up. Fluorodeoxyglucose
(FDG) positron emission tomography/computed tomography (PET/CT), based on the glucose
metabolism of malignant cells, plays a role in describing tumor growth, proliferation of neoplasm
and the extent of metastasis. In general, concordant findings of skeletal metastasis are seen on
both types of image, especially in cases of breast and lung cancer. However, there were extremely
discordant findings of skeletal metastasis between bone scans and F18 FDG PET/CT imaging in
two cases among 300 consecutive F18 FDG PET/CT follow-up exams of patients with malignan-
cies, during the past year, in our center. Both cases, one of breast cancer and one of lung cancer,
had negative bone scintigraphic findings, but a diffusely high grade of F18 FDG avid marrow
infiltration in the axial spine, leading to the diagnosis of stage IV disease in both cases. Owing to
variant genetic aberrance of malignance, F18 FDG PET/CT reveals direct evidence of diffuse,
rapid neoplasm metabolism in the bone marrow of the spine, but not of secondary osteoblastic
reactions in vivo. F18 FDG PET/CT should always be employed in the follow-up of patients with
malignancies.
Key Words: F18 FDG PET/CT, skeletal metastasis, Tc99m MDP bone scintigraphy
(Kaohsiung J Med Sci 2007;23:639–46)
The material in this article first appeared in poster form at the 9th World Federation of Nuclear
Medicine and Biology (WFNMB) Congress in Seoul, Korea, October 2006.
Kaohsiung J Med Sci December 2007 • Vol 23 • No 12640
Y.W. Chen, M.Y. Huang, J.S. Hsieh, et al
in up to 70% of patients with advanced breast or
prostate cancer [2], and in approximately 15–30% of
patients with carcinomas of the lung, colon, stomach,
bladder, uterus, rectum, thyroid or kidney. Bone metas-
tases have been characterized as osteolytic, osteoblastic
or mixed lesions containing both elements [3]. Most
patients with breast cancer have predominantly oste-
olytic lesions, although at least 15–20% of them have
predominantly osteoblastic lesions [4]. Once tumors
metastasize to bone, they are usually incurable: only
20% of patients with breast cancer are still alive 5 years
after the discovery of bone metastasis [5].
Tc99m methyl diphosphate (MDP) bone scintigra-
phy, which is a cost-effective and useful tool in wide-
spread disease, is the most commonly used means of
detecting bone metastasis and has variable diagnostic
sensitivity with comparatively low specificity. How-
ever, F18 fluorodeoxyglucose (FDG) positron emis-
sion tomography/computed tomography (PET/CT)
based on the glucose metabolism of malignant cells,
may describe tumor growth, proliferation of neoplasm
and the extent of metastasis, including distal skeletal
involvement. In general, concordant findings of skele-
tal metastasis are seen on both types of image, espe-
cially in those of breast and lung cancers. However,
there were extremely discordant findings of skeletal
metastasis between bone scans and F18 FDG PET/CT
in two cases among 300 consecutive F18 FDG PET/
CT follow-up exams during the past year in our PET
center.
CASE PRESENTATIONS
Case 1
A 51-year-old male patient with chronic cough for
more than 3 weeks in February (2006) had received
clinic medication to no avail, and was admitted for
advanced diagnosis. Tracing his history, only duode-
nal ulcer and acute appendicitis post appendectomy,
20 years ago, were revealed. He was, however, a heavy
smoker and habitually chewed betel nut. Initially, a
large soft mass in the right lower lobe (RLL) of the
lung was seen on chest X-ray, and thoracic CT sug-
gested lung cancer with mediastinal nodal involve-
ment. Based on imaging, the stage was considered to
be IIIb, T3N2Mx. Pathology demonstrated adenocar-
cinoma, which was determined to be grade II after
CT-guided biopsy. Tc99m MDP skeletal scintigraphy
revealed only a hot spot in the right anterior sixth rib,
heterogeneous lower grade of Tc99m MDP activity in
the spine, and extraosseously faint Tc99m MDP activity
in the RLL lung mass, as shown in Figure 1. Less con-
vincing evidence of distal bony metastases was found
by a bone scan in March. The patient then received his
first course of chemotherapy. F18 FDG PET/CT was
arranged for treatment follow-up due to an uncontrol-
lable lung mass on chest X-ray after 1 month.
Extremely discordant imaging patterns between
F18 FDG PET/CT and bone scans were seen, as shown
in Figure 2. Diffusely extensive spotty high-grade F18
FDG avid marrow activity was distributed in the
spine, pelvis and proximal long bone, but there was
no obvious lytic or sclerotic bony destruction on CT.
A higher grade of RLL lung mass with central necro-
sis and mediastinal nodal activity was also noted, but
the patient was free of hepatic metastases. Under 
F18 FDG PET/CT, stage IV disease was diagnosed.
Radiotherapy and gefitinib treatment were planned
for aggressive control in subsequent months. Another
Tc99m MDP bone scan was arranged for July, and a
lower grade of Tc99m MDP with heterogeneous pat-
tern in the lumbar spine, bilateral proximal long bones
and the old hot spot in the right anterior sixth rib
were detected. However, the patient died in late July
due to poor hemodynamic function, hepatic failure
from severe hepatic metastases and pancytopenia.
Case 2
A 53-year-old female with left breast cancer (infil-
trative ductal carcinoma with negative immuno-
chemistry of ER/PR/Her2neu) had received modified
radical mastectomy in October 2003. Chemotherapy
and radiation therapy were also arranged. She had
her follow-up in the city hospital. Tc99m MDP skeletal
scintigraphy was arranged to be administered annu-
ally. On serial Tc99m MDP scans, there was a hot spot
in the left hemivertebral body of L2 with mildly 
progressive activity. Therefore, possible degenerative
change was considered first, as shown in Figure 3.
However, progressive elevation of the tumor marker
CA153 to over 130 IU/mL was noted. Under an im-
pression of distal metastases, F18 FDG PET/CT was
arranged. Typically, multiple high-grade F18 FDG avid
osteolytic bony metastases in the spine, pelvis and
proximal long bones were seen, as shown in Figure 4.
Magnetic resonance imaging also demonstrated distal
bony metastases. Due to severe pathologic fractures,
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Figure 1. Two MDP skeletal scintigraphies were performed in early March and July. Visualized activity in both soft tissue and kidneys
did not support the diagnosis of the super scan. Initial skeletal imaging in March revealed tiny spot activity in the right anterior aspect
of the sixth and fourth ribs, heterogeneous spinal activity and extraosseous tumor activity in the right lower lobe of the lung. The second
skeletal imaging in July showed diffusely heterogeneous increased MDP activity in bilateral proximal humerus, femur and sacroiliac
joint. Although a progressive change in the MDP scintigraphic pattern was seen, less convincing evidence of typical multiple bony
metastases was demonstrated.
Figure 2. FDG PET/CT was performed later in March due to restaging of lung adenocarcinoma. Unfortunately, a large high-grade
FDG avid pulmonary mass with central necrosis, conglomerated bilateral mediastinal/supraclavicle nodal activity, right pleural effu-
sion and extremely disseminated heterogeneous nest-like high-grade FDG avid neoplasm metastatic foci within the marrow cavity of
the spine, pelvis, rib cage and bilateral proximal long bones were seen on FDG PET/CT. Stage IV disease and poor prognosis were indi-
cated. However, no evidence of hepatic metastasis was demonstrated by FDG PET/CT at this time.
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Figure 3. Anterior and posterior views of skeletal scintigraphy in: (A) 2005; (B) 2006. Progressively heterogeneous MDP activity in
the posterior aspect of L2 (arrow) and faint activity in L3 were seen between serial annual skeletal scintigraphies. However, no overt
evidence of abnormal MDP activity in the rest of the skeletal system was noted. Based on one spinal hot lesion and elevation of serum
CA153, FDG PET/CT was arranged for further evaluation.
A B
Figure 4. (A) Magnetic resonance imaging (MRI). (B) FDG PET/CT. An L2 pathologic compression fracture (thin arrows) is demon-
strated on MRI and FDG PET/CT. Multiple vertebral bony metastases (thick arrows) in the T/L spine and sacrum are also seen on
MRI and FDG PET/CT, but are discordant with the findings of serial skeletal scintigraphy. Diagnosis of osteolytic bone metastases
is favored.
she received surgical fixation. Final pathology showed
bony metastasis of breast cancer (Figure 5).
DISCUSSION
High blood flow, certain adhesive molecules of tumors
and a large repository of immobilized growth factors,
including transforming growth factor-β, insulin-like
growth factor I and II, fibroblast growth factors,
platelet-derived growth factors, bone morphogenetic
proteins and calcium, together, result in bone becom-
ing the preferred site of metastases [3]. These growth
factors, which are released and activated during bone
resorption, provide a fertile ground in which tumor
cells can grow. Stephan Paget first proposed the “seed-
and-soil hypothesis” to explain the mechanism of bone
metastasis in 1889, and animal models of bone metas-
tasis support this hypothesis [1]. During normal bone
turnover, there is a balanced remodeling sequence:
osteoclasts resorb bone first and then osteoblasts
form bone at the same site. Osteoclasts arise from
precursor cells in the monocyte-macrophage lineage
[6], and these differentiate into inactive osteoclasts.
Expression of receptor activator of nuclear factor-κB
ligand (RANKL) and macrophage colony stimulating
factor by stroma cells or osteoblasts plays a critical
role in the maturation of osteoclasts.
Most osteotropic factors, such as parathyroid hor-
mone, 1,25-dihydroxyvitamin D3 and prostaglandins,
induce the formation of osteoclasts by increasing the
expression of RANKL on marrow stroma cells and
osteoblasts, rather than by acting directly on osteo-
clast precursors [7,8]. The ratio of RANKL to osteo-
protegerin regulates the formation and activity of
osteoclasts. Osteoclasts resorb bone by secreting pro-
teases that dissolve the matrix and produce acid that
releases bone mineral into the extracellular space
under the ruffled border of the plasma membrane of
osteoclasts, which faces bone and is the resorbing
organelle of the cell. Osteoblasts, the bone-forming
cells, arise from mesenchymal stem cells, which form
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Figure 5. Pathology shows: (A) infiltrative ductal carcinoma of
the breast; (B, C) malignant bony metastasis from bony fragment
after fixation of pathologic fracture. [Figures provided by United
City Hospital, Kaohsiung, Taiwan.]
osteoblasts, adipocytes and muscle cells. CBFA1 (core-
binding factor α1) is a critical factor for the differen-
tiation of osteoblasts, and many growth factors can
enhance the maturation of these cells. However, the
differentiation of osteoblasts is less well understood
than that of osteoclasts.
We are familiar with purely osteolytic bone destruc-
tive metastasis in multiple myelomas, due to osteoblas-
tic dysfunction with unknown etiology. However,
overproduction of urokinase-type plasminogen acti-
vator (u-PA) by prostate-cancer cells increases bone
metastasis [9]. Prostate cancer cells also release
prostate-specific antigen and kallikrein, a serine pro-
tease, which can cleave parathyroid hormone (PTH)-
related peptide, resulting in block of tumor-induced
bone resorption [3]. Kallikrein may also activate osteo-
blast growth factors. Bone metastases from prostate
cancer are predominantly osteoblastic, with increased
numbers of irregular bone trabeculae [10].
In osteolytic metastases, the destruction of bone is
mediated by osteoclasts rather than tumor cells [11,12].
However, the factors responsible for the activation 
of osteoclasts vary depending on the tumor. Several
osteoclastogenic factors have been implicated in the in-
creased activity of osteoclasts, including interleukin-1,
interleukin-6, macrophage inflammatory protein 1α
and RANKL. In the vicious cycle of osteolytic metas-
tasis, especially in breast cancer, tumor cells secrete
PTH-related peptide as the primary stimulator of osteo-
clastogenesis. In addition, tumor cells produce other
factors that increase the formation of osteoclasts,
including interleukin-6, prostaglandin E2, tumor
necrosis factor and macrophage colony-stimulating
factor. These factors increase the expression of receptor
activator of RANKL, which acts directly on osteoclast
precursors to induce the formation of osteoclasts and
bone resorption.
In Case 2, there was progressive Tc99m MDP accu-
mulation in L2, probably related to osteoblastic remod-
eling after pathologic fracture. However, the other
multiple high-grade F18 FDG avid osteolytic metas-
tases in the T/L spines and pelvis, observed by mag-
netic resonance imaging and F18 FDG PET/CT, are
not consistent with Tc99m MDP skeletal scintigraphy
for osteoblastic activity. Distal marrow/bone metas-
tases of solid malignant neoplasms, such as those 
of breast cancer/lung cancer, have variable patterns
of osteoblastic/osteolytic activity. Therefore, moni-
toring bony metastases should be based on multiple
imaging modalities, in addition to Tc99m MDP skele-
tal scintigraphy (which was the only modality used
traditionally).
In Case 1, the patient with lung adenocarcinoma,
extremely discordant imaging results were found
among the osteoblastic activity detected by Tc99m MDP
skeletal scintigraphy, osteolytic activity detected by
skeletal CT and marrow activity detected by F18 FDG
PET. Based on this phenomenon, we considered the
case to be one of diffusely high-grade FDG avid neo-
plasm occupying the marrow, but not evoking an effect
on osteocytes. Homogeneously reactive marrow activ-
ity post chemotherapy seems less likely. Unfortunately,
this finding is consistent with poor prognosis [13],
despite shrinkage of tumor size after radiation therapy.
F18 FDG PET/CT should always be employed to detect
marrow/bony metastases in detail, following screen-
ing studies using Tc99m MDP skeletal scintigraphy.
REFERENCES
1. Paget S. The distribution of secondary growths in can-
cer of the breast. Lancet 1889;1:571–3.
2. Coleman RE, Rubens RD. The clinical course of bone
metastases from breast cancer. Br J Cancer 1987;55:61–6.
3. Roodman GD. Mechanisms of bone metastasis. N Engl
J Med 2004;350:1655–64.
4. Coleman RE, Seaman JJ. The role of zoledronic acid 
in cancer: clinical studies in the treatment and preven-
tion of bone metastases. Semin Oncol 2001;28(Suppl 6):
11–6.
5. Coleman RE. Metastatic bone disease: clinical features,
pathophysiology and treatment strategies. Cancer Treat
Rev 2001;27:165–76.
6. Roodman GD. Cell biology of the osteoclast. Exp
Hematol 1999;227:1229–41.
7. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast 
differentiation factor is a ligand for osteoprotegerin/
osteoclastogenesis-inhibitory factor and is identical to
TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:
3597–602.
8. Hofbauer LC, Heufelder AE. Osteoprotegerin and its
cognate ligand: a new paradigm of osteoclastogenesis.
Eur J Endocrinol 1998:139:152–4.
9. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase
overproduction results in increased skeletal metastasis
by prostate cancer cells in vivo. Cancer Res 1994;54:
2372–7.
10. Roudier MP, Vesselle H, True LD, et al. Bone histology
at autopsy and matched bone scintigraphy findings in
patients with hormone refractory prostate cancer: the
effect of bisphosphonate therapy on bone scintigraphy
results. Clin Exp Metastasis 2003;20:171–80.
Kaohsiung J Med Sci December 2007 • Vol 23 • No 12644
Y.W. Chen, M.Y. Huang, J.S. Hsieh, et al
11. Taube T, Elomaa I, Blomquvist C, et al. Histomorpho-
metric evidence for osteoclast-mediated bone resorp-
tion in metastatic breast cancer. Bone 1994;15:161–6.
12. Boyde A, Maconnachie E, Reid SA, et al. Scanning elec-
tron microscopy in bone pathology: review of methods,
potential and applications. Scan Electron Microsc 1986;
4:1537–54.
13. Prevost S, Boucher L, Larivee P, et al. Bone marrow
hypermetabolism on FDG PET as survival prognostic
factor in non-small-cell lung cancer. JNM 2006;47:559–65.
Discordant findings between F18 FDG PET/CT imaging and bone scan
Kaohsiung J Med Sci December 2007 • Vol 23 • No 12 645
646 Kaohsiung J Med Sci December 2007 • Vol 23 • No 12
 !"VS==N==NV=
 !"VS==Q==OR=
 !"#$%&'
 !"!#$ %&' !(
 UMT !"#$NMM
 !"#$%&'()*+,-.
 !"#$%&'()*+,-.
 !"#$== !"
 !
 
NIS
= = 
OIS
= = 
PIS
= = 
PIRIS
 
QIS
= = 
T
 !"!#$ %= =
N
 !"= =
O
 !"= =
P
 !"#= =
Q
 != =
R
 !
S
 !"!= = !
T
 !"#$%&'(%= = !"#
 !=VVã= !"#$%&'()*+,-./$0123456789
 !"#$%&'()*+,-./0123 456789:;<-./=
 !"#$%&'(!)*+,*-./0123456789:;<=>
 !"#$%&'()*+,-./0123456789*+:;<=>?
 !"#$%&'()*+,-./0123)456789:0;<3=,-
 !"#$%&'()*+,-./0123456/78-9:;%<=>
 !"#$%&'()*+,-./01"23456789:5;<=>?@
 !"#$%&'()#$*+,-./012345$6789:2;<=
 !"#$%&#'()!*+,-./0123!456789:;<=>?
 !"#$%&'()*+,-./"01234
  !"#$%&'()*+,-./0-123456.7+,
E !=OMMTXOPWSPVQSF
